HMGN3-AS1: A Promising Drug Target / Biomarker (G100288198)

Target Name: HMGN3-AS1

NCBI ID: G100288198

HMGN3-AS1

Other Name(s): HMGN3 antisense RNA 1

HMGN3-AS1: A Promising Drug Target / Biomarker

HMGN3-AS1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the stem-cell niche and has been shown to play a role in the development and maintenance of cancer. In this article, we will explore the biology of HMGN3-AS1, its potential as a drug target, and its potential as a biomarker for cancer.

Structure and Expression:
HMGN3-AS1 is a small non-coding RNA molecule that is expressed in a variety of tissues and cells. It is characterized by a unique stem-like structure that includes a long stem-loop and several exonic sequences that are involved in its stability and translation into protein. HMGN3-AS1 is typically expressed at a level of around 100 nM and is expressed in a variety of tissues, including stem cells, tissues derived from the skin, and tissues derived from the gut.

Function:
HMGN3-AS1 is a key regulator of the stem-cell niche. It has been shown to play a role in the maintenance of stem-cell stem-like characteristics and in the regulation of stem-cell proliferation. HMGN3-AS1 has also been shown to play a role in the development and maintenance of cancer. In particular, it has been shown to be involved in the development of skin cancer and in the regulation of cancer stem cells.

Potential as a Drug Target:
HMGN3-AS1 is a potential drug target due to its involvement in the development and maintenance of cancer. It has been shown to be involved in the regulation of stem-cell proliferation and in the development of cancer stem cells. As such, HMGN3-AS1 may be an attractive target for small molecule inhibitors that can be used to treat a variety of cancers.

Potential as a Biomarker:
HMGN3-AS1 may also be a useful biomarker for cancer. Its expression is often reduced in cancer cells compared to normal tissues, and it has been shown to be involved in the regulation of cancer cell growth and survival. As such, HMGN3-AS1 may be a useful biomarker for detecting the presence of cancer and for evaluating the effectiveness of cancer treatments.

Conclusion:
In conclusion, HMGN3-AS1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its unique stem-like structure and its involvement in the regulation of the stem-cell niche make it an attractive target for small molecule inhibitors. Its potential as a drug target and biomarker make it a promising molecule for the development of new cancer therapies. Further research is needed to fully understand its biology and its potential as a drug and biomarker.

Protein Name: HMGN3 Antisense RNA 1

The "HMGN3-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HMGN3-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets